The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer|Robert Wassman, MD,Rosetta Genomics Ltd 00:10:00
Rosetta Genomics, Ltd. announced that E. Robert Wassman, M.D. and Dganit Bar, Ph.D. will join the company in the newly created positions of Chief Medical Officer and Chief Scientific Officer, respectively, as of October 22, 2012. Prior to joining Rosetta Genomics, Dr. Wassman was Chief Medical Officer, Executive Vice President & Chief Genomics Officer at Generation Health. Dr. Bar joins Rosetta Genomics with 12 years of experience in drug development.
